Peptron

Focus: Peptron is a Korea-based biotechnology company specializing in peptide-based medicine platforms, positioned to develop novel therapeutic solutions leveraging peptide chemistry.

Metabolic Diseases Oncology Neurology

Profile data last refreshed 20h ago · AI intelligence enriched 1w ago

Open Jobs

About Peptron

AI assessmentNot Hiring

No open roles listed right now. Follow Peptron to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

leuprorelin acetate 3.75mg

Prostate Cancer

Phase 1

Clinical Trials (1)

NCT04783636To Compare the Safety and Pharmacokinetics of PT105 With PT105R in Healthy Postmenopausal Female Volunteers

Phase 1

Help build intelligence for Peptron

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to build a platform company in an underexplored modality (peptide therapeutics) with potential for significant IP creation
Korea-based location offers exposure to Asia-Pacific biotech ecosystem and emerging market advantages
Early-stage environment provides ownership and broad responsibility for career builders willing to take equity upside

Watch Out For

No active clinical programs, revenue, or published pipeline visibility—execution risk is extremely high
Lack of disclosed funding, employee count, and financial data creates uncertainty around runway and organizational maturity

Generated by Claude from Peptron's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

SR Exenatide

Type 2 Diabetes Mellitus

Phase 1

Clinical Trials (1)

NCT00964262A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide

Phase 1

PT320 2.0mg Placebo

Early Parkinson's Disease

Phase 2

Clinical Trials (1)

NCT04269642SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease

Phase 2